Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
4.24 USD | +0.47% | +14.59% | +13.37% |
05-10 | Piper Sandler Adjusts Fate Therapeutics' Price Target to $4 From $7, Keeps Neutral Rating | MT |
05-10 | Wedbush Adjusts Fate Therapeutics' Price Target to $5 From $7, Keeps Neutral Rating | MT |
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
SubscribeEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+13.37% | 480M | |
+7.52% | 111B | |
+11.38% | 106B | |
-12.64% | 22.24B | |
+0.44% | 21.25B | |
-4.18% | 18.97B | |
-37.85% | 18.52B | |
-8.58% | 16.81B | |
+37.41% | 12.54B | |
-23.95% | 8.09B |
- Stock Market
- Equities
- FATE Stock
- News Fate Therapeutics, Inc.
- Transcript : Fate Therapeutics, Inc., Q3 2020 Earnings Call, Nov 05, 2020